Baird Maintains Outperform on Astrana Health, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Michael Ha maintains an Outperform rating on Astrana Health (NASDAQ:ASTH) and raises the price target from $54 to $67.
August 15, 2024 | 10:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Michael Ha maintains an Outperform rating on Astrana Health and raises the price target from $54 to $67.
The raised price target and maintained Outperform rating from a reputable analyst are likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100